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The Coronavirus disease (COVID-19) has affected the 
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and 3.29 deaths worldwide as of May 10, 2021. The 
only drug in allopathic medicine approved by United 
States Food and Drug Administration for treating 
COVID-19 infections is remdesivir; approved only for 
use in adults and pediatric population > 12 years (and 
weighing at least 88 pounds) and requiring 
hospitalization.[1] Since April 2021, there has been a 
second wave of COVID-19 infections in Indian sub-
continent that has taken a huge surge of lives and 
shortage in the remdesivir supply was observed 
during this difficult time. Ayurveda is one of the 
world’s oldest healing system and is one of the vital 
complementary and alternative systems of medicine. 
Ayurveda classifies an individual based on Tridoshas 
theory into one of the following types of Prakriti: 
A B S T R A C T  
Background: There is so far no proven treatment for the unprecedented COVID-19 infections. Ayurveda holds 
promise in the treatment of this viral infection. We carried out a randomized controlled trial of ‘AyurCoro-3’, a 
combination of Gomutra (Bos indicus urine), hot water, turmeric, Turati Churna (potassium Alum), candy sugar 
(Khadisakhar), Bos indicus milk with two teaspoons of Go Ghrut (Ghee) as an adjuvant to standard care, in 
comparison to standard care alone in patients with mild-to-moderate COVID-19 infections. Methods: A 
randomized, blinded, controlled trial was carried out in adult patients diagnosed with mild-to-moderate COVID-19 
infections confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) test. Interventional group was 
administered single dose of ‘AyurCoro-3’ as an adjuvant with standard care, and the control group received only 
standard of care. Validated clinical improvement scale was used for evaluating the clinical improvement, time of 
resolution of presenting symptoms, duration of hospitalization, proportion of patients requiring mechanical 
ventilation, and functional status scale were the key outcomes. Results: One-hundred and seventy-four patients 
were recruited. Significantly more proportions of patients had resolution of all symptoms (cough, fever, 
breathlessness, weakness, and tastelessness) in the interventional group compared to control. Similarly, the 
interventional group also had shorter time for clinical improvement as well as shorter time of resolution for cough, 
breathlessness, and weakness. No significant differences were observed in the duration of hospitalization, 
proportion of patients requiring mechanical ventilation, functional status scale, and adverse events between the 
groups. Conclusion: The Ayurvedic medicine ‘AyurCoro-3’ was observed to significantly shorten the duration of 
COVID-19 infections and was well tolerated.  
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Vata, Pitta and Kapha. Vata is related to motion, pitta 
to metabolism, and Kapha to lubrication.[2] Even 
several centuries ago, a holistic approach (physical, 
psychological, philosophical, ethical, and spiritual 
health) and personalized treatment based on their 
constitutional profile has been documented in 
Ayurveda.[3] Ayurveda has been shown to successfully 
cure many of the chronic diseases.[4] Although widely 
practiced, due to lack of documented scientific 
evidence, Ayurveda is still not accepted 
substantially.[5] There is documentation in Ayurveda 
related to deranged Vayu (air), Jala (water), Desha 
(habitat) and Kala (seasons) imbalance resulting in 
widespread air/water-borne infections killing mass 
population resembling the COVID-19 pandemic.[6]  
Based on the preliminary documentation in standard 
Ayurvedic texts, we formulated ‘AyurCoro-3’ 
containing a combination of cow (Bos Indicus) urine, 
turmeric (Curcumin), potassium alum, candy sugar, 
Bos indicus’s milk, and ghee. Bos indicus urine has 
been shown to possess broad-spectrum antimicrobial 
activity including multi-drug resistant Escherichia coli 
and Klebsiella pneumonia.[7] A preliminary data 
revealed that urine can enhance the recovery from 
COVID-19 infections.[8] Curcumin has been shown in 
several studies to effectively neutralize human 
immunodeficiency virus, Zika virus, Dengue virus, 
Chikungunya virus, and influenza virus.[9] Aluminum 
salts have been shown to possess antibacterial, 
antiviral, and immunogenic properties and alum is a 
common adjuvant used in several vaccines to boost 
the immunity.[10] Hence, the ‘AyurCoro-3’ combination 
has a potential to effectively treat patients with 
COVID-19 infections and hence the present study was 
envisaged. 
METHODOLOGY 
Study ethics and study design 
The study was initiated after obtaining approval from 
the Institutional Ethics Committee and approval from 
the Ministry of Health (EC/NEW/INST/2019/245). 
Written informed consent was obtained from each of 
the study participants. The study was randomized, 
blinded, controlled trial comparing ‘AyurCoro-3’ as 
and adjuvant to the standard of care with standard of 
care in patients with mild-to-moderate COVID-19 
infections. The study was carried out in hospitals 
dedicated for treating COVID-19 patients approved by 
Government of India, between October 2020 and 
March 2021 in compliance to the latest update of 
Declaration of Helsinki guidelines. The study 
procedure details are stated in (Electronic 
supplementary Table 1) 
Study participants 
Adult patients (>18 years) of either sex presenting 
with symptoms and signs of mild-to-moderate COVID-
19 infections confirmed by reverse transcriptase 
polymerase chain reaction (RT-PCR) test were 
recruited. Mild-to-moderate infections were 
characterized by the presence of symptoms of mild 
pneumonia, with respiratory rate less than 30/minute, 
blood oxygen saturation (SpO2) > 90%, ratio of partial 
pressure of oxygen in the blood to fractional inspired 
oxygen concentration (PaO2/FiO2) ratio < 300, and 
absence of any altered mental state/multiple organ 
failure.[11] Those who were pregnant or breastfeeding, 
requiring mechanical ventilation, history of 
allergies/hypersensitivity reactions were excluded. 
Patients with uncomplicated upper respiratory tract 
infections, with mild symptoms such as fever, cough 
sore throat, nasal congestion, malaise, and headache 
were classified as ‘mild COVID-19 disease’. Presence 
of symptoms mimicking pneumonia (without signs of 
severe disease) was considered as ‘moderate COVID-
19 disease’. 
Treatment arms 
Standard of care (common to both the treatment 
groups) 
Mild COVID-19 infections  
▪ Symptomatic management with paracetamol 
orally 500 milligram every six hours for fever/pain.  
▪ Adequate nutrition/rehydration.  
▪ In the presence of risk factors such as age > 60 
years, hypertension, diabetes, chronic 
lung/kidney/liver disease, cerebrovascular disease 
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and obesity, hydroxychloroquine orally (day 1: 
400 mg twice on the first day and 200 mg twice a 
day for another four days) was administered.  
Moderate COVID-19 infections 
▪ Oxygen was administered using nasal 
prongs/mask/masks with breathing/non-
rebreathing reservoir bag.  
▪ Hydroxychloroquine at the above-mentioned 
dosing regimen was administered to all patients.  
▪ Methylprednisolone at 0.5 to 1 mg/kg/day 
intravenously for 3 days in case of increased 
requirement of oxygen or elevated erythrocyte 
sedimentation rate and/or C-reactive protein.  
▪ In case of anticoagulation requirement, 
unfractionated/enoxaparin (low molecular weight 
heparin) was administered.  
Interventional arm 
In addition to the standard of care, this group 
received ‘AyurCoro-3’ administered three times on 
their baseline visit. ‘AyurCoro-3’ consists of:  
▪ Bos Indicus urine/hot water/turmeric to be 
gargled twice a day. First gargle one hour prior to 
lunch around 12 PM and second gargle around 9 
PM. 
▪ Turati Churna (potassium Alum) with candy sugar 
(Khadisakhar) in half a glass of warm water mixed 
with bos indicus urine 10 ml, orally. The first dose 
of this intervention was started one hour post 
lunch, the second dose was administered two 
hours post first dose, and the third dose after two 
hours following the second dose. 
▪ One glass (200 ml) of pure Bos indicus milk with 
two teaspoons of Go Ghrut (Ghee) was 
administered post one hour of the third oral dose. 
For each patient, a fresh preparation of the above 
complex was carried out just before administration.  
Outcomes 
▪ Proportion of patients with clinical improvement: 
Clinical assessments were carried out on days 3, 5, 
and 7 following initiation of treatment. Resolution 
of clinical symptoms/signs was considered as 
clinical improvement. Ordinal scale for Clinical 
improvement scale (Electronic supplementary 
Table 2) was used. 
▪ Time of resolution of baseline symptoms.  
▪ Duration of hospitalization.  
▪ Proportion of participants requiring mechanical 
ventilation any time during the hospitalization.  
▪ Proportion of patients with 2-point improvement 
in 8-point ordinal scale for clinical improvement.  
▪ Functional status scale (Electronic Supplementary 
Table 3) assessed after 7 and 14 days, following 
hospital discharge.  
▪ Adverse event and serious adverse events (during 
their hospital stay and days 7 and 14 after 
discharge). 
Study procedure 
Eligible patients were randomized to either control or 
interventional arm and were hospitalized until their 
recovery. Outcomes of interest were evaluated at 
baseline, days 3, 5, and 7 after randomization. The 
following symptoms were evaluated for assessing the 
clinical improvement: fever, cough, breathlessness, 
weakness, and tastelessness. Following their 
discharge from the hospital, patients were followed-
up for assessment of any adverse events on days 7 
and 14. The clinical improvement and functional 
status scales were validated for their reliability in an 
initial cohort of 10 patients who were not included in 
the main study (kappa value of 0.85 was observed). 
Statistical analysis 
With a power of 80% and type 1 error rate of 5%, a 
clinically significant difference of 10% and 10% lost to 
follow-up, 87 patients were estimated per each group. 
Computer-generated random number sequence was 
used for randomization, and the generated 
randomization list was concealed using opaque and 
sealed envelope until the evaluation of eligible 
patients. The study members involved in evaluating 
the response to treatment and statisticians involved in 
data analysis were blinded to the treatment 
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allocation. Descriptive statistics was used for 
representing the demographic variables. Intention to-
treat analysis was carried out. Numerical data was 
evaluated for normal distribution using Kolmogorov-
Smirnov test and accordingly either parametric or 
non-parametric test was used. Statistical analyses 
were done using ‘R version 4.0.2’, Python 3 and ‘SPSS 
version 20’. A p-value < 0.05 was considered 
significant. We adhered to the Consolidated Standards 
of Reporting Trials (CONSORT) statement in reporting 
this clinical trial.[12]   
RESULTS 
Demographics 
Two-hundred and twelve patients were screened of 
which 38 were excluded and 174 were finally 
recruited. The study flow diagram is represented in 
Figure 1. Eighty-seven were recruited in each of the 
arms and four died in the control arm. A summary of 
demographic characteristics of the study participants 
are represented in Table 1. Nearly half-of the study 
participants in each arm presented with cough and 
breathlessness. 
Proportion of patients with clinical improvement 
Proportions of patients experiencing various 
symptoms at baseline, and at each follow-up day until 
discharge are depicted in Figure 2 and Electronic 
Supplementary Figure 1. Significantly more 
proportions of patients had resolution of all the 
symptoms on day 3 in the interventional group 
compared to control arm (p<0.05). Odds ratios for 
symptom resolution are represented in Table 2 
comparing each of the symptoms on days 3, 5, and 7 
compared to baseline. Significantly fewer patients had 
cough, breathlessness, weakness, and fever on day 3 
in the interventional group compared to control arm. 
Similarly, on day 5, significantly fewer patients had 
cough, taste disturbances, and weakness in the 
interventional group compared to control arm. On day 
7, significantly fewer patients had cough in the 
interventional arm compared to control group. 
Median (range) values of the ordinal scale for clinical 
improvement scale in the interventional compared to 
control groups were as follows: Day 1: [3 (3), 4 (3); 
p=0.7]; day 3: [2 (2), 3 (3); p<0.0001]; and day 5: [2 
(2), 3 (3); p<0.0001]; day 7: [2 (2), 2 (4); p<0.0001]; 
discharge: [1 (0), 1 (8); p=0.001]  
Time of resolution of symptoms 
Significantly shorter time of resolution [mean (SD)] 
were observed for cough [9.3 (4.1), 11.9 (3.6) days; p 
< 0.0001], breathlessness [9.2 (6.1), 11 (6.7) days; p = 
0.0009], and weakness [9.5 (2.9), 11.5 (3.7) days; p < 
0.0001] with the interventional arm compared to the 
control group. We did not observe any significant 
(p>0.05) differences in the time taken for resolution 
of other symptoms [taste disturbance: 8.9 (3.4), 7.2 
(3.3) days; and fever: 9.8 (6), 9.7 (3.6) days]. 
Duration of hospitalization 
Median (range) of duration of stay in the hospital in 
the interventional group was 9 (39) days and in the 
control group 10 (31) days and was not statistically 
significant (p=0.4). 
Proportion of participants requiring mechanical 
ventilation any time during the hospitalization 
In the interventional arm, 1(1.14%) required 
mechanical ventilation while 4 (4.5%) in the control 
arm needed and it was not statistically significant 
(p=0.4).   
Proportion of patients with 2-points improvement in 
the clinical improvement scale 
Thirty-four (39.08%), 44 (50.57%), 58 (66.66%), 
85(97.70%) on days 3, 5, 7, and on the day of 
discharge respectively in patients in the interventional 
group showed 2-points improvement in the scale 
compared to 13 (14.94%), 19(21.83), 27(31.03%), 
71(81.60%) in the control group and it was 
significantly different (p < 0.001). The odds ratios for 
2-points improvement in the scores in the 
interventional group compared to control were as 
follows: Days 3, 5, 7, and on the day of discharge 
compared to baseline were 2.85 [1.4, 5.7], 3.02 [1.6, 
5.7], 3.8 [2, 7.1], and 9.6 [2.1, 43] respectively. 
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Functional status scale 
Median (range) of functional status scores in the 
interventional group was 1(3) for each of the groups 
on days 7 and 15, and it was not statistically 
significant (p=0.99).  
Adverse event and serious adverse events 
The number of patients reporting various adverse 
events during their stay in the hospital, on days 7 and 
15 after discharge are represented in Table 3. No 
serious adverse events other than death of four 
patients in the control arm were observed.  
DISCUSSION 
In the light of several controversies revolving around 
the treatment options for COVID-19 infections, the 
present study carries significant importance as we 
have evaluated the clinical utility of ‘AyurCoro-3’ as an 
adjuvant to the standard of care in mild-to-moderate 
infections. We observed that significantly high 
proportion of patients receiving this Ayurvedic 
treatment had most of their presenting symptoms 
resolved, as well as their time of resolution were 
much shorter compared to the control group. No 
significant differences were observed in the functional 
status after discharge, proportion of patients 
requiring mechanical ventilation, and adverse events 
between the groups. To the best of our knowledge, 
this is the first randomized, blinded clinical trial on 
this Ayurvedic combination for treating COVID-19 
infections. As the COVID-19 pandemic was sudden, 
inadvertent, and unanticipated, it was impossible to 
discover new drugs to clear the viral infections. 
Hence, many investigators were involved in 
identifying the potential repurposing of the existing 
drugs as possible treatment options for COVID-19 
infections. Various initiatives were taken from the 
Government of India to evaluate and establish any 
effective therapy for prevention/treatment from 
Ayurveda, Yoga and Naturopathy, Unani, Siddha, and 
Homoeopathy; clinical trials evaluating the efficacy 
and safety of Withania somnifera, Tinospora cordifolia 
(Thunb.) and Glycyrrhiza glabra are ongoing.[13] We 
observed that our ‘AyurCoro-3’ as adjuvant provides 
more rapid relief of COVID-19 related symptoms 
compared to standard of care alone. Like most of the 
complementary and alternative treatment options, 
since the present study has provided preliminary 
evidence for ‘AyurCoro-3’ in ameliorating COVID-19 
symptoms, it is the need of the hour to do ‘reverse 
pharmacology’ exploring the exact mechanism of anti-
viral activity. In vitro studies evaluating the dose-
response relationship on the cytopathic effect of the 
ingredients used in ‘AyurCoro-3’ needs to be 
explored. Bos Indicus urine contains various nutrients 
such as iron, calcium, phosphorus, salts, carbonic acid, 
potash, nitrogen, ammonia, manganese, sulphur, 
phosphate, potassium, urea, uric acid, amino acids, 
enzymes, cytokines, lactose that may act as immune 
boosters.[14] Curcumin has been observed to exert 
antiviral activity against coronavirus through multiple 
modes: inhibiting the entry of viral proteins; inhibits 
viral protease activity, reduces interleukin - 6 and 
nuclear factor-kappa β activity.[15] The ingredients 
used in ‘AyurCoro-3’ are easily available in India (and 
in several developing countries) that it is relatively 
easier to cater the needs of the pandemic than 
synthetic/allopathic drugs. We did not observe any 
significant adverse events associated with this 
Ayurvedic combination. We have empirically used 
single dose of this Ayurvedic preparation and future 
studies shall explore the therapeutic benefit of 
prolonged administration. Further, future studies 
should focus on ‘AyurCoro-3’ as adjuvant for patients 
with more severe COVID-19 infections. Also, cost-
effective studies are also needed to understand its 
utility in resource-limited nations/healthcare set-ups. 
The strengths of the study are as follows: the design 
of the study was randomized, and triple blinded; a 
strict definition of mild-to-moderate coronavirus 
infection was adhered with evidence of infection 
based on RT-PCR test; and objective, validated scales 
were used for evaluating the response of the 
interventions. The study is limited in not evaluating 
the viral loads in the respiratory secretions/antiviral 
titer; genotyping of the virus causing infections was 
not carried out; and RT-PCR test was not repeated 
daily. 
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CONCLUSION 
We observed that our Ayurvedic medicine ‘AyurCoro-
3’ was associated with significantly shorter time of 
resolution of symptoms in patients with mild-to-
moderate COVID-19 infections. This Ayurvedic 
medicine was also well tolerated. 
FUNDING 
The funder of the study had no role in the study 
design, data collection, data analysis, data 
interpretation or writing of the report. The 
corresponding author had full access to all the data in 
the study and had final responsibility for the decision 
to submit for publication.  
Figure 1: Study flow diagram 
    
This diagram depicts the flow of study participants 
from screening until the final follow-up days. 
Figure 2. Proportion of patients with improvement in 
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The diagram represents the proportion of patients 
with each of the COVID-19 related symptoms at each 
follow-up days in both the groups. 
Table 1: Demographic characteristics of the study 
participants (N=174) 





Age (years)α 55.48 (48.27)  52.70 (45.48)  
Sex (male)  58 (66.66 %) 65 (74.71 %) 
Coexisting diseases  
Hypertension 16 (18.39 %)  20 (22.98 %) 
Ischemic heart disease  3 (3.45%) 2 (2.30%) 
Diabetes mellitus 11 (12.64%) 11 (12.64%) 
Proportion of Symptoms  
Cough 51 (58.62%) 64 (73.56%) 
Breathlessness 45 (51.72%) 35 (40.23%) 
Tastelessness 5 (5.75%) 13 (14.94%) 
Fever  21 (24.14%) 25 (28.74%) 
Weakness 44 (50.57%) 46 (52.87%) 
Deaths  4 (4.5%) 0 (0%) 
Duration of oxygen 
requirement (days)α   
5.8 (6.38) 3.2 (1.50) 
α – represented in mean (SD). All others are represented in n (%). 
Table 2: Odds ratios [95% confidence intervals] of 
COVID-19 symptoms on each follow-up days 
compared to baseline in the interventional groups. 

















































































































α – Statistically significant.  
Table 3: Adverse events reported in the study 
participants. 
 Variable Hospital Stay Post Discharge 
 at Day-7 
follow-up 
Post Discharge 














Nausea 1 3 0 1 0 0 


































Proportion of Patients experiencing 
Tastelessness
Intervention Control
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0 2 0 1 0 1 
Disturbed 
sleep 
0 2 0 2 0 1 
Loose 
Motion 
1 2 0 1 0 1 
Headache 1 1 0 4 0 1 
Skin 
Dryness 
0 1 0 1 0 0 
Burning 
micturition 
0 0 0 2 0 0 
Table 4: Clinical trial study procedure 









1 Signed Informed 
Consent Form  
X         
2 Medical History X         
3 Clinical 
Examination 
X X X X   
4 Review of 
eligibility 
criteria1 
X         
5 Vital signs and 
Demography2,3 
X         








 X X X  
9 Functional 
status scale5 
     X  




X         
12 Concomitant 
Medications 
X         
13 Safety Follow 
Up Visit 
        X 
AE= Adverse Event, SAE=Serious Adverse Event 
Footnotes:  
1 - Eligibility Criteria confirmed at D1 after informed consent 
procedure 
2 - Vital Signs Included: Pulse, BP, SPO2 
3 - Demography features captured in the case record form 
included age, gender. 
4 - AyurCoro-3 medication compliance sheet was maintained to 
assess compliance with the study medicine. 
5 - Blinded Study team member conducted telephonic follow up 
 6 - Adverse events (AE) were defined as any new symptoms or 
worsening of pre-existing symptoms and were followed until 
complete resolution of symptoms. Serious adverse events (SAE) 
were defined as per the New Drug Clinical Trials - 2019 guidelines 
and ICMR 2017 guidelines. SAEs were reported to the 
"Bhaktivedanta Hospital Ethics Committee for Biomedical and 
Health Research” for independent adjudication of relatedness. 
SAEs were graded for causality. Investigators reviewed SAE’s for 
medical management and compensation. 
Table 5: Clinical improvement scale 
1. Discharge 
2. Hospital admission no symptoms for consecutive 
2 days 
3. Hospital admission with symptoms 
4. Hospital admission symptoms with experimental 
drugs like remdesivir. 
5. Hospital admission symptoms with requiring 
supplemental oxygen 
6. Hospital admission symptoms requiring high flow 
nasal cannula or non-invasive mechanical 
ventilation 
7. Hospital admission symptoms requiring invasive 
mechanical ventilation 
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8. Death 
Table 6: Functional status scale 
1. I have no limitations in my daily routine activities 
and no symptoms, pain, depression, or anxiety 
related to the infection.  
2. I have no limitations in my daily routine activities 
and no symptoms, but I have anxiety related to 
the infection.  
3. I have negligible limitations in my daily routine 
activities, and no symptoms, pain, depression, or 
anxiety related to the infection.  
4. I have negligible limitations in my daily routine 
activities, but I still have persistent symptoms, 
pain, depression, or anxiety.  
5. limitations in my everyday life disturbs my routine 
activities due to which I am unable to perform 
most of the activities, but I do not need nursing 
help as I can still do activities independently  
6. limitations in my everyday life disturbs my routine 
activities due to which I am unable to perform 
most of the activities. I need nursing help 
however I do not think hospital admission is 
required.  
7. limitations in my everyday life disturbs my routine 
activities due to which I am unable to perform 
most of the activities. I need nursing help. I 
strongly feel that I need hospital admission. 
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